These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34598656)

  • 1. A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
    Taprogge J; Gape PMD; Carnegie-Peake L; Murray I; Gear JI; Leek F; Hyer SL; Flux GD
    Thyroid; 2021 Dec; 31(12):1829-1838. PubMed ID: 34598656
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
    Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
    Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
    Markovic V; Eterovic D
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry-based treatment for Graves' disease.
    Hyer SL; Pratt B; Gray M; Chittenden S; Du Y; Harmer CL; Flux GD
    Nucl Med Commun; 2018 Jun; 39(6):486-492. PubMed ID: 29613968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease.
    Willemsen UF; Knesewitsch P; Kreisig T; Pickardt CR; Kirsch CM
    Eur J Nucl Med; 1993 Nov; 20(11):1051-5. PubMed ID: 8287872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine therapy for Graves' disease - retrospective analysis of efficacy factors.
    Szumowski P; Abdelrazek S; Kociura Sawicka A; Mojsak M; Kostecki J; Sykała M; Myśliwiec J
    Endokrynol Pol; 2015; 66(2):126-31. PubMed ID: 25931042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine (131I) therapy of Graves' disease: use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland.
    Nagayama Y; Ashizawa K; Matsuo K; Inoue S; Harakawa S; Hirayu H; Yamashita S; Izumi M; Nagataki S
    Endocrinol Jpn; 1989 Jun; 36(3):359-65. PubMed ID: 2684619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy.
    Flower MA; al-Saadi A; Harmer CL; McCready VR; Ott RJ
    Eur J Nucl Med; 1994 Jun; 21(6):531-6. PubMed ID: 8082669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.